J. Sefton

发表

Photodamage pilot study: a double-blind, vehicle-controlled study to assess the efficacy and safety of tazarotene 0.1% gel.

A. Kligman, J. Sefton, A. Kligman, 2000, Journal of the American Academy of Dermatology.

Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.

M. Lebwohl, J. Koo, G. Krueger, 2003, Journal of the American Academy of Dermatology.

The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.

P. Elias, G. Krueger, G. Weinstein, 1998, Archives of dermatology.

Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.

A. Shalita, E. Tschen, D. Chalker, 1999, Cutis.

Tazarotene plus UVB phototherapy in the treatment of psoriasis.

J. Koo, N. Lowe, J. Sefton, 2000, Journal of the American Academy of Dermatology.

Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.

M. Lebwohl, G. Weinstein, B. Goffe, 1997, Journal of the American Academy of Dermatology.

Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris.

J. Leyden, A. Shalita, J. Sefton, 1987, Journal of the American Academy of Dermatology.

Efficacy of a sunscreen containing butyl methoxydibenzoylmethane against ultraviolet A radiation in photosensitized subjects.

R. Gange, J. Sefton, S. Dromgoole, 1986, Journal of American Academy of Dermatology.

Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks.

J. Leyden, J. Ortonne, Sewon Kang, 2001, Archives of dermatology.

Indoor and outdoor efficacy testing of a broad-spectrum sunscreen against ultraviolet A radiation in psoralen-sensitized subjects.

N. Lowe, J. Sefton, T. Bourget, 1987, Journal of the American Academy of Dermatology.

Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Naftifine Gel Study Group.

L. Drake, J. Jorizzo, C. Ellis, 1991, Cutis.

In vitro and in vivo cutaneous penetration and antifungal activity of naftifine.

R. Stoughton, J. Sefton, L. Zeleznick, 1989, Cutis.

Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis.

L. Millikan, J. Sefton, S. Horwitz, 1988, Journal of the American Academy of Dermatology.

Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis.

L. Millikan, A. Hebert, J. Sefton, 1992, Journal of the American Academy of Dermatology.

Naftifine cream 1% in cutaneous candidiasis

J. Sefton, N. Zaias, R. Rojas, 1989 .

Naftifine cream in the treatment of cutaneous candidiasis.

J. Sefton, R. Day, N. Zaias, 1988, Cutis.

A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage.

Sewon Kang, G. Krueger, P. Walker, 2005, Journal of the American Academy of Dermatology.

Histological effects of tazarotene 0·1% cream vs. vehicle on photodamaged skin: a 6‐month, multicentre, double‐blind, randomized, vehicle‐controlled study in patients with photodamaged facial skin

P. Walker, J. Sefton, T. Rist, 2004, The British journal of dermatology.

A pilot study to determine the effect of tazarotene gel 0.1% on steroid‐induced epidermal atrophy

J. Sefton, S. Kopper, J. R. Gibson, 2001, International journal of dermatology.

Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.

G. Krueger, G. Weinstein, M. Duvic, 1997, Journal of the American Academy of Dermatology.

Once‐Daily Naftifine Cream 1% in the Treatment of Tinea Cruris and Tinea Corporis

R. Rapini, R. Jordon, H. Katz, 1990, International journal of dermatology.

Addition of a topically applied corticosteroid to a modified Goeckerman regimen for treatment of psoriasis: effect on duration of remission.

J. Sefton, P. Frost, S. Horwitz, 1985, Journal of the American Academy of Dermatology.

Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial.

A. Gottlieb, J. Leyden, T. Phillips, 2002, Archives of dermatology.

Response of psoriasis to a new topical retinoid, AGN 190168.

M. Duvic, J. Sefton, R. Chandraratna, 1994, Journal of the American Academy of Dermatology.

Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.

J. Leyden, D. Thiboutot, A. Shalita, 2004, Clinical therapeutics.

Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.

M. Lebwohl, J. Callen, T. Phillips, 1998, Journal of the American Academy of Dermatology.

Clinical evaluation of hydrocortisone valerate 0.2% ointment.

J. Sefton, A. Kyriakopoulos, J. Loder, 1984, Clinical therapeutics.

The safety and efficacy of naftifine cream 1% in the treatment of tinea pedis

J. Sefton, L. Schachner, I. Willis, 1990 .

Pharmacokinetics of Tazarotene Cream 0.1% After a Single Dose and After Repeat Topical Applications at Clinical or Exaggerated Application Rates in Patients with Acne Vulgaris or Photodamaged Skin

Zhiling Yu, P. Walker, J. Sefton, 2003, Clinical pharmacokinetics.

DEVELOPMENT OF RAR SUBTYPE SELECTIVE RETINOIDS FOR DERMATOLOGICAL DISEASES

L. Wheeler, S. Nagpal, M. Garst, 1995, European Journal of Medicinal Chemistry.